This bill proposes to classify xylazine as a Schedule III controlled dangerous substance (CDS) in New Jersey, with the exception of its use in veterinary medicine. The new legal language specifies that xylazine and its various forms will be included in Schedule III, which is reserved for substances that have a potential for abuse less than those in Schedules I and II, have accepted medical use, and may lead to moderate or low physical dependence. The bill outlines the penalties for illegal activities related to xylazine, including manufacturing, distribution, and possession, which could result in third-degree criminal charges, with potential imprisonment and fines.

The rationale behind this classification stems from the increasing presence of xylazine in illegal street drugs, particularly opioids, where it is used to enhance euphoric effects. However, xylazine is not an opioid and does not respond to opioid antidotes, posing significant overdose risks. The bill aims to mitigate these dangers by regulating xylazine more strictly, thereby protecting public health and safety in New Jersey. The Director of the Division of Consumer Affairs will be responsible for implementing the necessary rules and regulations to enforce this new classification.

Statutes affected:
Introduced: 24:21-7